| Pack Size | Single Vial, 10-Pack |
|---|
Sermorelin (acetate) is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth-hormone-releasing hormone, GHRH(1-29). It is the shortest fully functional fragment of GHRH and is studied as a growth-hormone secretagogue acting at the GHRH receptor. Every batch is independently third-party tested by HPLC for purity and mass spectrometry for identity, to a minimum of 99 percent purity. Supplied as a lyophilized powder for laboratory research use only.
Description
Sermorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), reproducing residues 1 through 29 of the native 44-amino-acid hormone. Research established early that this 29-residue fragment retains the full biological activity of the parent hormone, making it the shortest fully functional GHRH sequence. It carries a C-terminal amide and is commonly supplied as the acetate salt.
In the research-supply context, Sermorelin is a standard tool for studying the growth-hormone axis. Rather than supplying growth hormone directly, it acts upstream at the pituitary to stimulate the body's own pulsatile GH synthesis and release, which is why it is studied as a growth-hormone secretagogue. It is provided here strictly as a research-grade reagent.
Mechanism in research literature
Sermorelin binds the growth-hormone-releasing-hormone receptor (GHRHR), a class-B G-protein-coupled receptor expressed on the somatotroph cells of the anterior pituitary. Receptor engagement activates adenylate cyclase, raises intracellular cyclic AMP, and drives the synthesis and pulsatile secretion of endogenous growth hormone. Because it works through the physiological GHRH pathway, the resulting GH release retains its pulsatile character and remains subject to negative feedback from somatostatin and IGF-1.
This upstream, feedback-preserving mechanism is the feature most emphasised in the literature and the basis on which Sermorelin is compared with other growth-hormone secretagogues such as the longer-acting GHRH analogue CJC-1295 and the ghrelin-receptor agonists.
Studied properties
Documented areas of Sermorelin research include: GHRH-receptor pharmacology; stimulation of endogenous, pulsatile growth-hormone release; the growth-hormone/IGF-1 axis; and its historical use as a diagnostic tool for assessing pituitary GH-secretory capacity. These describe the published research landscape and are provided for scientific context only. They are not claims of efficacy. Ronin Peptides supplies Sermorelin exclusively as a research-grade reagent and provides no dosing protocols or therapeutic recommendations.
Compound specifications
| Compound | Sermorelin acetate (GHRH 1-29) |
|---|---|
| CAS number | 86168-78-7 (sermorelin; acetate salt supplied) |
| Molecular formula | C149H246N44O42S |
| Molecular weight | 3,357.9 g/mol |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 |
| Length | 29 amino acids (C-terminal amide) |
| Class | GHRH-receptor agonist / GH secretagogue |
| Form | Lyophilized white-to-off-white powder |
| Vial contents | 5 mg peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by a third-party analytical lab) |
Storage and handling
Store unopened lyophilized vials dry and cold; long-term storage should be at or below −20 °C, protected from light and moisture. Once reconstituted, keep refrigerated at 2–8 °C and use within a few weeks; avoid repeated freeze–thaw cycles. Bring vials to room temperature before opening.
Compare with similar compounds
Sermorelin is a GHRH-analogue growth-hormone secretagogue and is most directly compared with other GHRH analogues. It is shorter-acting than CJC-1295, which adds modifications that extend its half-life; and it differs mechanistically from the ghrelin-receptor agonists such as Ipamorelin, which stimulate GH release through a separate receptor. Researchers frequently study a GHRH analogue and a ghrelin-receptor agonist together to examine their complementary actions on the somatotroph. Sermorelin is also compared with Tesamorelin, a stabilised GHRH analogue.
Reconstitution and laboratory handling
A 5 mg vial of Sermorelin reconstituted with 2 mL of bacteriostatic water yields a final concentration of 2.5 mg/mL, or 2,500 mcg/mL. Other diluent volumes scale linearly: 1 mL gives 5 mg/mL, 5 mL gives 1 mg/mL.
- Bring both vials to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake.
- Invert slowly or swirl gently until dissolved. Do not vortex or shake.
- Refrigerate at 2–8 °C.
Frequently asked questions
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide reproducing GHRH(1-29), the shortest fully functional fragment of growth-hormone-releasing hormone. It is studied as a growth-hormone secretagogue acting at the GHRH receptor.
How does Sermorelin differ from CJC-1295?
Both are GHRH analogues, but CJC-1295 carries modifications that substantially extend its half-life, whereas Sermorelin is shorter-acting and closely mirrors native GHRH(1-29).
What is the regulatory status of Sermorelin?
The research-grade material supplied here is for laboratory research use only, not for human or veterinary use.
How is Sermorelin verified?
Each batch passes through an independent third-party analytical lab for HPLC purity and mass-spectrometry identity confirmation, to a minimum of 99 percent purity.
How do I receive the COA for my batch?
A certificate of analysis is available for your specific batch on request, tied to your lot.
References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 1999. PMID 18031173.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical interventions in aging. 2006. PMID 18046908.
- Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine reviews. 1993. PMID 8491152.
